GlassScriptPhysician profile
Ali Hadi
NPI 1972034734
$16,091.07
in general payments reported to CMS, 2019-2025
30 companies · $7,865 in 2025
The $7,865 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $664 · 2023: $798 · 2024: $6,664 · 2025: $7,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,313 · Food and Beverage: $5,224 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,455 · Education: $278 · Travel and Lodging: $57.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,312.50 |
| Food and Beverage | $5,223.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,455.00 |
| Education | $277.86 |
| Travel and Lodging | $57.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,027.11 | 2023-2025 | |
| Eli Lilly and Company | $3,000.00 | 2024 | Taltz |
| Abbvie INC. | $2,700.58 | 2022-2025 | |
| Janssen Biotech, INC. | $2,320.12 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $586.90 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $557.50 | 2022-2025 | |
| Lilly USA, LLC | $452.20 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $318.61 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $275.98 | 2022-2025 | |
| Leo Pharma INC. | $270.31 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $239.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $226.37 | 2021-2022 | |
| Dermavant Sciences, INC. | $214.86 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $141.09 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $131.99 | 2023-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $123.81 | 2023-2025 | Zoryve |
| Medtronic, INC. | $82.99 | 2024-2025 | Minimed 780g |
| Amgen INC. | $58.17 | 2022-2025 | Otezla, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $57.03 | 2023-2025 | Sotyktu |
| Glaxosmithkline, LLC. | $47.02 | 2023-2024 | Trelegy Ellipta |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.08 | 2024-2025 | Siliq |
| Xeris Pharmaceuticals, INC. | $45.03 | 2024-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $42.86 | 2023 | Ozempic, Rybelsus |
| Organon LLC | $21.78 | 2025 | Vtama |
| Abbott Laboratories | $19.24 | 2023 | Freestyle Libre 3 |
| Almirall LLC | $18.83 | 2023 | Klisyri |
| Botanix Sb INC | $18.65 | 2025 | Sofdra |
| Ascendis Pharma Endocrinology INC | $18.30 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.93 | 2023 | Spevigo |
| Merck Sharp & Dohme LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.